RAAV5-miHTT

( DrugBank: rAAV5-miHTT / KEGG DRUG: - )

1 disease

ID	Disease name (Link within this page)	Number of trials
8	Huntington disease	4

8. Huntington disease

Clinical trials : 242 / Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159

trials per page:

Showing 1 to 4 of 4 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05243017 (ClinicalTrials.gov)	October 7, 2021	1/11/2021	Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease	A Phase Ib/II Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Dose ...	Huntington Disease	Genetic: intra-striatal rAAV5-miHTT	UniQure Biopharma B.V.	NULL	Recruiting	25 Years	65 Years	All	15	Phase 1/Phase 2	Germany;Poland;United Kingdom
2	EUCTR2020-001461-36-DE (EUCTR)	13/09/2021	30/04/2021	Safety and Efficacy of AMT-130 in European Adults with Early Manifest Huntington Disease	A Phase Ib/II Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Dose ...	Huntington Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's di ...	Product Name: rAAV5-miHTT Product Code: AMT-130	uniQure biopharma B.V.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	15	Phase 1;Phase 2	Poland;Germany;United Kingdom
3	EUCTR2020-001461-36-PL (EUCTR)	30/06/2021	25/03/2021	Safety and Efficacy of AMT-130 in European Adults with Early Manifest Huntington Disease	A Phase Ib/II Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Dose ...	Huntington Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's di ...	Product Name: rAAV5-miHTT Product Code: AMT-130 Other descriptive name: ADENO-ASSOCIATED VIRUS SEROTYP ...	uniQure biopharma B.V.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	15	Phase 1;Phase 2	Poland;United Kingdom
4	NCT04120493 (ClinicalTrials.gov)	September 6, 2019	30/9/2019	Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Dise ...	A Phase I/II, Randomized, Double-Blind, Sham Control Study to Explore Safety, Tolerability, and Effi ...	Huntington's Disease	Genetic: intra-striatal rAAV5-miHTT;Other: Imitation (sham) surgery	UniQure Biopharma B.V.	NULL	Recruiting	25 Years	65 Years	All	44	Phase 1/Phase 2	United States

First Previous1Next Last